These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9697078)

  • 1. Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen.
    Tod M; Alet P; Lortholary O; Petitjean O
    J Pharmacokinet Biopharm; 1997 Dec; 25(6):695-712. PubMed ID: 9697078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
    Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
    Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian approach to drug disposition evaluation: application to teicoplanin.
    Ferrante L; Bompadre S; Cingolani ML; Leone L
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):410-4. PubMed ID: 7582399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic study of teicoplanin in severely neutropenic patients.
    Lortholary O; Tod M; Rizzo N; Padoin C; Biard O; Casassus P; Guillevin L; Petitjean O
    Antimicrob Agents Chemother; 1996 May; 40(5):1242-7. PubMed ID: 8723474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
    Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
    Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical Information.
    Yamada T; Emoto C; Fukuda T; Motomura Y; Inoue H; Ohga S; Ieiri I
    Ther Drug Monit; 2022 Jun; 44(3):404-413. PubMed ID: 34629445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of software for data analysis by therapeutic drug monitoring of teicoplanin, a glycopeptide antibiotic].
    Niwa T; Tokuma Y; Ito T; Kimura J; Tabata K; Takagi A
    Jpn J Antibiot; 2004 Aug; 57(4):413-9. PubMed ID: 15535042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teicoplanin pharmacokinetics in pediatric patients.
    Dufort G; Ventura C; Olivé T; Ortega JJ
    Pediatr Infect Dis J; 1996 Jun; 15(6):494-8. PubMed ID: 8783345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal loading regimen and achievement of trough concentrations for teicoplanin using Japanese population parameters.
    Hiraki Y; Yasumori N; Nagano M; Inoue D; Tsuji Y; Kamimura H; Karube Y
    Int J Antimicrob Agents; 2015 Jan; 45(1):87-8. PubMed ID: 25459402
    [No Abstract]   [Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.
    Ramos-Martín V; Neely MN; McGowan P; Siner S; Padmore K; Peak M; Beresford MW; Turner MA; Paulus S; Hope WW
    J Antimicrob Chemother; 2016 Nov; 71(11):3168-3178. PubMed ID: 27543654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of teicoplanin concentrations and safety analysis in neonates.
    Yamada T; Kubota T; Nakamura M; Ochiai M; Yonezawa M; Yano T; Kawashiri T; Egashira N; Hara T; Masuda S
    Int J Antimicrob Agents; 2014 Nov; 44(5):458-62. PubMed ID: 25218156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections.
    Ogami C; Tsuji Y; Muraki Y; Mizoguchi A; Okuda M; To H
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):175-188. PubMed ID: 30934169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-centre retrospective observational study comparing trough blood concentration and safety of teicoplanin formulations.
    Shinoda R; Shinoda Y; Ohashi K; Matsuoka T; Hirose T; Sugiyama T; Yoshimura T
    J Infect Chemother; 2019 Jul; 25(7):563-566. PubMed ID: 30929977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.
    Lamont E; Seaton RA; Macpherson M; Semple L; Bell E; Thomson AH
    J Antimicrob Chemother; 2009 Jul; 64(1):181-7. PubMed ID: 19411678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
    Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y
    Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.